Abstract:BCR‐ABL1 gene fusion associated with additional DNA lesions involves to the pathogenesis of chronic myelogenous leukemia (CML) from a chronic phase (CP) to a blast crisis of B lymphoid (CML‐LBC) lineage and BCR‐ABL1+ acute lymphoblastic leukemia (BCR‐ABL1+ ALL). The recombination‐activating genes RAG1 and RAG2 (collectively, RAG) proteins that assemble a diverse set of antigen receptor genes during lymphocyte development are abnormally expressed in CML‐LBC and BCR‐ABL1+ ALL. However, the direct involvement of dysregulated RAG in disease progression remains unclear. Here, we generate human wild type (WT) RAG and catalytically inactive RAG expressing BCR‐ABL1+ and BCR‐ABL1‐ cell lines, respectively, and demonstrate that BCR‐ABL1 specifically collaborates with RAG recombinase to promote cell survival in vitro and in xenograft mice models. WT RAG expressing BCR‐ABL1+ cell lines and primary CD34+ bone marrow cells from CML‐LBC samples maintain more double strand breaks (DSBs) compared to catalytically inactive RAG expressing BCR‐ABL1+ cell lines and RAG deficient CML‐CP samples, which are measured by γ‐H2AX. WT RAG expressing BCR‐ABL1+ cells are biased to repair RAG‐mediated DSBs by the alternative non‐homologous end joining pathway (a‐NHEJ), which could contribute genomic instability via increasing expressions of a‐NHEJ related MRE11 and RAD50 proteins. As a result, RAG expressing BCR‐ABL1+ cells decrease sensitivities to tyrosine kinase inhibitors (TKIs) by activating BCR‐ABL1 signaling but independent of the levels of BCR‐ABL1 expression and mutations in BCR‐ABL1 tyrosine kinase domain. These findings identify a surprising and novel role of RAG in the functional specialization of disease progression in BCR‐ABL1+ leukemia through its endonuclease activity

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the role and mechanism of recombination - activating genes (RAG1 and RAG2) in BCR - ABL1 - positive leukemia cells. Specifically, the study aims to clarify how RAG enhances the growth of BCR - ABL1 - positive leukemia cells through its endonuclease activity and to explore whether this process is related to the choice of DNA damage repair pathways, especially the alternative non - homologous end - joining (a - NHEJ) pathway. In addition, the study also investigates how RAG expression affects the sensitivity of these cells to tyrosine kinase inhibitors (TKI) and the potential role of RAG in the transformation of chronic myeloid leukemia (CML) from the chronic phase to the acute lymphoblastic crisis (CML - LBC). ### Research Background - **BCR - ABL1 Fusion Gene**: Associated with chronic myeloid leukemia (CML) and BCR - ABL1 - positive acute lymphocytic leukemia (BCR - ABL1+ ALL). - **RAG Proteins**: Assemble diverse antigen receptor genes during lymphocyte development, but are abnormally expressed in CML - LBC and BCR - ABL1+ ALL. - **Core of the Problem**: The direct role of RAG in disease progression is unclear, especially its function in BCR - ABL1 - positive leukemia cells. ### Main Findings - **RAG Promotes the Survival of BCR - ABL1 - Positive Cells**: Through its endonuclease activity, RAG cooperates with BCR - ABL1 to promote cell survival in vitro and in xenograft mouse models. - **DNA Damage Repair**: BCR - ABL1 - positive cells with wild - type RAG expression maintain more double - strand breaks (DSB), which are mainly repaired through the a - NHEJ pathway, leading to increased genomic instability. - **Reduced Sensitivity to TKI**: BCR - ABL1 - positive cells with RAG expression reduce their sensitivity to TKI by activating the BCR - ABL1 signaling pathway, independently of the BCR - ABL1 expression level and mutations. - **Validation in Clinical Samples**: The expression levels of RAG and γ - H2AX are higher in CD34+ bone marrow cells of CML - LBC patients, supporting the role of RAG in disease progression. ### Conclusion This study reveals a new role of RAG in BCR - ABL1 - positive leukemia, especially the importance of its endonuclease activity in disease progression. These findings provide a new perspective for understanding the mechanism of the transformation of CML from the chronic phase to the acute phase and may provide a theoretical basis for the development of new treatment strategies.

RAG enhances BCR‐ABL1 ‐positive leukemic cell growth through its endonuclease activity in vitro and in vivo